We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




MRI and PET Used with Solid Tumor Response Evaluation Criteria to Track Treatment in Bone Metastases

By LabMedica International staff writers
Posted on 22 Sep 2014
Imaging technologies are very useful in evaluating a patient’s response to cancer treatment, and this can be done quite effectively for most tumors using solid tumor response evaluation criteria.

RECIST (Response Evaluation Criteria in Solid Tumors), however, works well for tumors located in soft tissue, but not so well for cancers that spread to the bone, such as is the case for prostate and breast cancers. More...
More effort, therefore, is needed to improve the determination of how to monitor the response of bone metastases to treatment using magnetic resonance imaging (MRI) and positron emission tomography (PET). A recent European Organization for Research and Treatment of Cancer (EORTC; Brussels, Belgium) Imaging Group review and position statement published online August 16, 2014, in the European Journal of Cancer addresses the situation.

The article published by these EORTC Imaging Group investigators emphasized the most recent developments in MRI and PET and elucidates how these techniques can be used to identify bone metastases at an early stage as well as monitor the response of these to treatments. They described the current state of the art in PET and MRI, the strengths, weaknesses and complementarity of various imaging techniques with respect to specific indications, and recommendations for choosing the most appropriate imaging technique.

Prof. Frederic Lecouvet, from the Cliniques Universitaires Saint Luc (Brussels, Belgium), and lead author of this review and position statement, said, “Assessing the response of metastases to treatment is something we do on a day to day basis, both in our oncology practice as well as for clinical trials. If the metastases occur in soft tissues, then we already have validated criteria, such as RECIST, that enable us to evaluate the response. A host of problems, however, limits our ability to measure the response to treatment of metastases found in bone. These range from the characteristics of bone metastatic disease, the structure of bone itself, to the sensitivity, specificity, and resolution of imaging methods available until now. We hope to resolve these issues, and our review is a step in the right direction.”

Techniques such as MRI and PET have the potential to detect the metastasizing of a cancer into the bone marrow at an earlier stage and also determine the extent of this spread, and the efforts of the EORTC researchers should help towards making these techniques a routine part of oncology practice.

Related Links:

European Organization for Research and Treatment of Cancer
Cliniques Universitaires Saint Luc



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.